IMPACT seeks to interrupt malaria transmission
The fight against malaria is especially difficult in high-transmission areas. Insufficient access to long-lasting insecticidal nets, mosquitoes’ resistance to insecticides and changing mosquito behaviors need to be countered with innovative malaria control strategies.
There were 405,000 malaria-related deaths in 2018. Children under five years old accounted for 67 percent of the deaths.
Ivermectin is a drug that kills parasites and is used extensively in veterinary medicine. Recent studies have shown that ivermectin can also be used to interrupt malaria transmission.
The IMPACT project seeks to develop a long-acting injectable form of ivermectin that would be easier to administer and adhere to. It builds on the work of another Unitaid-supported project, BOHEMIA, which is focused on the use of oral ivermectin in vector control. IMPACT is also one of several Unitaid projects that are developing long-acting medicines for treatment or prevention of malaria, HIV, tuberculosis and hepatitis C.
The impact we are seeking
A long-acting injectable version of ivermectin could make an important contribution to the global goal of ending malaria as an epidemic by 2030. IMPACT’s product is to be quality-assured, affordable, and suitable for wide introduction in low- and middle-income countries.
Long-acting ivermectin promises to contribute to equitable access to health services because it would benefit areas that tend to have weak health systems. It also kills a variety of other disease-causing parasites that pose significant threats to health and livelihoods in low- and middle-income countries.